Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight
The vasomotor symptoms market is anticipated to increase during the forecast period (2026–2036), owing to improved diagnosis, treatment advancements, aging demographics, increased awareness, the launch of emerging therapies such as Cendifensine (NOE-115; Noema Pharma), Asimadoline (Tioga Pharmaceuticals), ABCL635 (AbCellera Biologics), Refisolone (PH80; Vistagen Therapeutics), and others, and healthcare spending across the 7MM.
LAS VEGAS, Sept. 30, 2026 /PRNewswire/ -- Recently published Vasomotor Symptoms Market Insights report includes a comprehensive understanding of current treatment practices, vasomotor symptoms emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Vasomotor Symptoms Market Summary
Discover the menopause-related vasomotor symptoms market @ https://www.delveinsight.com/report-store/vasomotor-symptoms-market
Key Factors Driving the Growth of the Vasomotor Symptoms Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that emerging assets such as cendifensine (NOE-115) and asimadoline (TP0052) may expand future treatment options through novel mechanisms; however, their adoption will depend on clinical efficacy, safety, regulatory approval, and differentiation from currently available therapies.
Vasomotor Symptoms Market Analysis
Vasomotor Symptoms Competitive Landscape
Some of the vasomotor symptoms drugs under development include Cendifensine (NOE-115; Noema Pharma), Asimadoline (Tioga Pharmaceuticals), ABCL635 (AbCellera Biologics), Refisolone (PH80; Vistagen Therapeutics), MNGX-100 (MenoGeniX), FP-101 (Fervent Pharmaceuticals), and others.
Noema Pharma's Cendifensine (NOE-115) is an investigational, non-hormonal therapy being developed by Noema Pharma for the treatment of menopausal vasomotor symptoms (VMS). It is an oral, once-daily, broad-spectrum monoamine modulator designed to influence monoaminergic pathways involved in thermoregulation and the management of menopausal symptoms.
Cendifensine is currently being evaluated in a Phase II clinical study in women experiencing moderate-to-severe VMS, including hot flashes and night sweats. The asset offers a novel non-hormonal treatment approach, with potential differentiation based on its broad monoamine modulation mechanism compared with more targeted therapies.
Tioga Pharmaceuticals' Asimadoline (TP0052) is an investigational non-hormonal therapy being developed by Tioga Pharmaceuticals for the treatment of menopausal vasomotor symptoms. It is a peripherally restricted, selective kappa opioid receptor agonist designed to modulate peripheral sensory and autonomic pathways involved in thermoregulation and the control of menopausal symptoms.
The asset is currently being evaluated in a Phase II clinical study designed to assess its safety and efficacy in women with moderate-to-severe menopausal vasomotor symptoms.
AbCellera Biologics' ABCL635 is an investigational, first-in-class antibody therapy being developed as a non-hormonal treatment for menopause-associated VMS, commonly referred to as hot flashes. The therapy selectively targets the neurokinin 3 receptor (NK3R), a clinically validated membrane protein expressed on KNDy neurons in the infundibular nucleus of the hypothalamus, which plays an important role in regulating body temperature.
ABCL635 is the first AbCellera-led program generated through the company's GPCR and ion channel technology platforms. It is currently being evaluated in a Phase I/II clinical trial to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and the frequency and severity of VMS following subcutaneous administration of ABCL635.
The anticipated launch of these emerging therapies are poised to transform the vasomotor symptoms market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the vasomotor symptoms market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the vasomotor symptoms treatment @ Vasomotor Symptoms Treatment Market
Recent Developments in the Vasomotor Symptoms Market
Vasomotor Symptoms Epidemiology Segmentation
The vasomotor symptoms epidemiology section provides insights into the historical and current vasomotor symptoms patient pool and forecasted trends for the leading markets. In the US, among women aged ≥65 years, 20.9-45.1% reported vasomotor symptoms; 2.0% reported severe symptoms, and 17.6% reported moderate symptoms.
The vasomotor symptoms treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Vasomotor Symptoms Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Vasomotor Symptoms Epidemiology Segmentation
Prevalent Vasomotor Symptoms Cases, Diagnosed Vasomotor Symptoms Prevalent Cases, Diagnosed Prevalent Vasomotor Symptoms Cases by Age, Diagnosed Vasomotor Symptoms Prevalent Cases by Severity, and Vasomotor Symptoms Treated Cases
Key Vasomotor Symptoms Companies
Noema Pharma, Tioga Pharmaceuticals, AbCellera Biologics, Vistagen Therapeutics, MenoGeniX, Fervent Pharmaceuticals, Pfizer, Astellas, Bayer, and others
Key Vasomotor Symptoms Therapies
Cendifensine (NOE-115), Asimadoline, ABCL635, Refisolone (PH80), MNGX-100, FP-101, DUAVEE, VEOZAH, LYNKUET, and others
Scope of the Vasomotor Symptoms Market Report
Download the report to understand the recent developments in the vasomotor symptoms market @ Vasomotor Symptoms Clinical Trials
Table of Contents
1
Vasomotor Symptoms Market Key Insights
2
Vasomotor Symptoms Market Report Introduction
3
Executive Summary of Vasomotor Symptoms
4
Key Events
5
Epidemiology and Market Methodology of Vasomotor Symptoms
6
Vasomotor Symptoms Market Overview at a Glance
6.1
Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2
Market Share of Vasomotor Symptoms by Therapy (%) in the 7MM in 2025
6.3
Market Share of Vasomotor Symptoms by Therapies (%) in the 7MM in 2036
7
Disease Background And Overview of Vasomotor Symptoms
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4
Related Conditions
7.5
Etiology
7.6
Risk Factors
7.7
Pathophysiology
7.8
Complications
7.9
Diagnosis
7.10
Management and Treatment
8
Epidemiology and Patient Population of Vasomotor Symptoms
8.1
Key Findings
8.2
Assumption and Rationale
8.3
Total Diagnosed Prevalent Cases of Vasomotor Symptoms in the 7MM
8.4
The US
8.4.1
Vasomotor Symptoms Prevalent Cases in the US
8.4.2
Vasomotor Symptoms Diagnosed Prevalent Cases in the US
8.4.3
Vasomotor Symptoms Diagnosed Prevalent Cases by Age in the US
8.4.4
Vasomotor Symptoms Diagnosed Prevalent Cases by Severity in the US
8.4.5
Vasomotor Symptoms Treated Cases in the US
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey of Vasomotor Symptoms
10
Marketed Therapies of Vasomotor Symptoms
10.1
Competitive Landscape of Marketed Therapies
10.2
Bazedoxifene acetate/conjugated estrogens (DUAVEE): Pfizer
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Clinical Trials
10.2.5
Analyst Views
10.3
Fezolinetant (VEOZAH): Astellas Pharma
11
Emerging Therapies of Vasomotor Symptoms
11.1
Competitive Landscape of Emerging Therapies
11.2
Cendifensine (NOE-115): Noema Pharma
11.2.1
Product Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trial Information
11.2.4
Safety and Efficacy
11.2.5
Analyst's View
11.3
Asimadoline: Tioga Pharmaceuticals
Continued emerging therapies will be provided in the final report.
12
Vasomotor Symptoms Market: Seven Major Market Analysis
12.1
Key Findings
12.2
Vasomotor Symptoms Market Outlook
12.3
Conjoint Analysis
12.4
Key Market Forecast Assumptions
12.5
Total Market Size of Vasomotor Symptoms in the 7MM
12.6
The US Vasomotor Symptoms Market Size
12.6.1
Total Market Size of Vasomotor Symptoms in the US
12.6.2
Market Size of Vasomotor Symptoms by Therapies in US
12.7
EU4 and the UK Vasomotor Symptoms Market Size
12.8
Japan Vasomotor Symptoms Market Size
13
Unmet Needs of Vasomotor Symptoms
14
SWOT Analysis of Vasomotor Symptoms
15
KOL Views of Vasomotor Symptoms
15.1
Expert/KOL Interview Highlights
16
Market Access and Reimbursement of Vasomotor Symptoms
16.1
The US
16.2
EU4 and the UK
16.3
Japan
16.4
Summary and comparison of Market Access and Pricing Policy Developments in 2025
16.5
Market Access and Reimbursement of Vasomotor Symptoms Therapies
17
Bibliography
18
Vasomotor Symptoms Market Report Methodology
Related Reports
Vasomotor Symptoms of Menopause Clinical Trial Analysis
Vasomotor Symptoms of Menopause Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key vasomotor symptoms of menopause companies, including Mithra Pharmaceuticals, Acer Therapeutics, QUE Oncology, Bayer, Endoceutics, Astellas Pharma, Mitsubishi Tanabe Pharma, MenoGenix, and others.
Menopause Market
Menopause Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key menopause companies, including Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others.
Hot Flashes Market
Hot Flashes Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, and others.
Hot Flashes Clinical Trial Analysis
Hot Flashes Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP